In patients with localized prostate cancer undergoing external beam radiotherapy, use of the orally administered androgen deprivation therapy relugolix results in rapid and sustained suppression of testosterone to castrate levels, with a tolerable safety profile, according to the results of a phase II trial.
Platinum-based neoadjuvant chemotherapy appears to be beneficial in patients with bulky regional lymph node metastases from penile cancer, with nearly 50 percent responding to treatment and about 16 percent achieving a pathological complete response, results of a systematic review and meta-analysis have shown.
The incidence of infection is similar between head and neck cancer patients who received antimicrobial prophylaxis and those who did not, results of a recent study have shown. In addition, no difference is observed in the incidence of hospitalization, but the length of hospital stay is longer in the prescribed prophylactic group.
Combination therapy with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors appears to be well tolerated and beneficial in pretreated patients with metastatic renal cell carcinoma (mRCC), suggests a recent study.
Concurrent docetaxel with radiotherapy (DOC-RT) is generally safe in elderly patients with oesophageal cancer (EC), though caution should be advised in the very old and undernourished, a recent study has shown.
The combination of gemcitabine plus albumin-bound paclitaxel (ABP) appears to be well tolerated and effective in the first-line treatment of patients with advanced squamous cell lung cancer (SQCLC), according to the results of a phase II study.
A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.
Hippocampal avoidance during whole-brain radiotherapy (HA-WBRT), together with memantine, better preserves cognitive function vs WBRT plus memantine in patients with brain metastases, without compromising survival, a multi-institutional phase III trial has shown.
Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.
At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.
“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.
Fasting-mimicking diet (FMD) cycles in combination with endocrine therapy (ET) cause metabolic changes in hormone receptor (HR)-positive breast cancer patients analogous to those observed in animal models, where they are associated with anticancer activity.